{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:33:38Z","timestamp":1792445618079,"version":"4.5.0"},"reference-count":21,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"unspecified","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. Psychiatr."],"published-print":{"date-parts":[[2026]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Trazodone is commonly used in the treatment of major depressive disorder (MDD) in adults. This study aimed to establish consensus on the clinical scenarios and patient profiles for which trazodone treatment is considered suitable.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A two-round Delphi process was conducted across eight European countries. Statements regarding trazodone were rated by a panel of 32 experts for agreement or disagreement using a 9-point Likert scale; those with <70% agreement among panelists were revised and reassessed by the panel.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There was strong consensus agreement on 68 out of 91 statements (75%) related to trazodone. According to the panel, trazodone is well tolerated, with low anticholinergic activity, minimal impact on sexual function, weight neutrality, and low potential for clinically relevant drug\u2013drug interactions. Consensus agreement supported trazodone use across a broad spectrum of patients with MDD, including those with insomnia, anxiety, psychomotor agitation, substance use, physical comorbidities, neurological conditions, and treatment-resistant depression; consensus agreement was also achieved for trazodone use in elderly patients, and those experiencing adverse effects with other antidepressants.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study suggests that trazodone is useful in the treatment of MDD across multiple patient profiles. These findings offer practical guidance to support individualized and evidence-based decision-making in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1192\/j.eurpsy.2026.10162","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:50:44Z","timestamp":1770360644000},"source":"Crossref","is-referenced-by-count":1,"title":["Expert consensus on the use of trazodone in patients with major depressive disorder: results from a European Delphi panel"],"prefix":"10.1192","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":false,"given":"Allan Hunter","family":"Young","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041kmwe10","id-type":"ROR","asserted-by":"publisher"}],"name":"King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Surgery, University of Siena"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Ag\u00fcera-Ortiz","sequence":"additional","affiliation":[{"name":"Complutense University of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3109-1895","authenticated-orcid":false,"given":"Marcin","family":"Siwek","sequence":"additional","affiliation":[{"name":"Jagiellonian University Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-191X","authenticated-orcid":false,"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[{"name":"Medical University of Vienna"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"S092493382610162X_r16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","article-title":"Effects of psychotropic drugs on seizure threshold","volume":"25","author":"Pisani","year":"2002","journal-title":"Drug Saf"},{"key":"S092493382610162X_r18","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/OnlineFirst\/174432"},{"key":"S092493382610162X_r21","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X21666230403080624"},{"key":"S092493382610162X_r5","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-023-00465-y"},{"key":"S092493382610162X_r13","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001630"},{"key":"S092493382610162X_r8","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2363843"},{"key":"S092493382610162X_r15","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000909"},{"key":"S092493382610162X_r12","first-page":"137","article-title":"Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice","volume":"54","author":"Cuomo","year":"2019","journal-title":"Riv Psichiatr"},{"key":"S092493382610162X_r7","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900024020"},{"key":"S092493382610162X_r4","first-page":"41","article-title":"Antidepressant adherence: are patients taking their medications?","volume":"9","author":"Sansone","year":"2012","journal-title":"Innov Clin Neurosci"},{"key":"S092493382610162X_r1","volume-title":"The global burden of disease: 2004 update","year":"2008"},{"key":"S092493382610162X_r10","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000722"},{"key":"S092493382610162X_r14","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0191"},{"key":"S092493382610162X_r3","first-page":"18","article-title":"Evaluating antidepressant therapies: remission as the optimal outcome","volume":"64","author":"Thase","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S092493382610162X_r6","unstructured":"[6] European Medicines Agency. Summary of Product Characteristics: Trazodone 150 mg tablets; n.d. https:\/\/www.medicines.org.uk\/emc\/product\/4975\/smpc."},{"key":"S092493382610162X_r9","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900006817"},{"key":"S092493382610162X_r2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"S092493382610162X_r17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1296639"},{"key":"S092493382610162X_r20","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198908000-00010"},{"key":"S092493382610162X_r11","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0010-5"},{"key":"S092493382610162X_r19","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198901001-00007"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S092493382610162X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:55:05Z","timestamp":1784271305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S092493382610162X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["S092493382610162X"],"URL":"https:\/\/doi.org\/10.1192\/j.eurpsy.2026.10162","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e36"}}